Combined heart and kidney transplantation in a patient with Fabry disease in the enzyme replacement therapy era

20Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Fabry disease (FD) is an X-linked genetic disease, resulting from the deficiency of alpha-galactosidase A, a lysosomal enzyme responsible for the cleavage of glycosphingolipids. In absence of enzyme replacement therapy (ERT), globotriaosylceramide (Gb3) accumulates in tissue, leading to progressive organ damage with severe renal, cardiac and central nervous system complications. We herein describe the first case of successful combined and simultaneous heart and kidney transplantation in a young male patient with FD complicated by end-stage renal disease and severe heart failure not responding to late-onset ERT. Combined heart and kidney transplantation can be recommended for Fabry patients with end-stage renal disease and overt hypertrophic cardiomyopathy, severe ischemic or valvular heart disease. © 2008 The Authors.

Cite

CITATION STYLE

APA

Karras, A., De Lentdecker, P., Delahousse, M., Debauchez, M., Tricot, L., Pastural, M., … Lidove, O. (2008). Combined heart and kidney transplantation in a patient with Fabry disease in the enzyme replacement therapy era. American Journal of Transplantation, 8(6), 1345–1348. https://doi.org/10.1111/j.1600-6143.2008.02245.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free